HOOKIPA Pharma Announces Board of Directors Changes
Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing immunotherapeutics based on its arenavirus platform, has announced significant changes to its Board of Directors. Julie O'Neill has been appointed as Non-Executive Chair, succeeding Jan van de Winkel, who is stepping down due to increasing commitments as CEO of Genmab A/S. Additionally, Tim Reilly is also leaving the Board to focus on other professional responsibilities. Both departures are effective August 30, 2024. The Board will now comprise five members, with the vacated seats remaining unfilled. O'Neill expressed gratitude for van de Winkel's seven years of service and Reilly's contributions, emphasizing her commitment to working with the management team for the benefit of shareholders and stakeholders.
Positive
- Appointment of Julie O'Neill as Non-Executive Chair, potentially bringing fresh perspectives to the Board
- Streamlined Board structure with reduction from seven to five members, potentially improving decision-making efficiency
Negative
- Loss of experienced Board members Jan van de Winkel and Tim Reilly
- Potential gap in expertise and industry connections due to departing Board members
News Market Reaction 1 Alert
On the day this news was published, HOOK gained 0.38%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O’Neill as Non-Executive Chair of the Company’s Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his other professional responsibilities.
“On behalf of the entire Board, I want to thank Jan for his more than seven years of loyal service and inspirational leadership of the Board of Directors and Tim for his insights and perspectives,” said Ms. O’Neill. “We understand their demanding schedules and are grateful for the years of service they provided HOOKIPA. I look forward to working with the management team on behalf of our shareholders and other stakeholders.”
Messrs. van de Winkel’s and Reilly’s board seats will remain unfilled, and the Board will comprise five members.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, KRAS-mutated cancers, and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead. Find out more about HOOKIPA online at www.hookipapharma.com.
For further information, please contact:
Investors
Chuck Padala
Managing Director, LifeSci Advisors
chuck@lifesciadvisors.com
Media
Tom Davies / Ashe Reardon
tom.davies@kekstcnc.com / ashe.reardon@kekstcnc.com
FAQ
Who is the new Non-Executive Chair of HOOKIPA Pharma's (HOOK) Board of Directors?
Why are Jan van de Winkel and Tim Reilly leaving HOOKIPA Pharma's (HOOK) Board?
How many members will HOOKIPA Pharma's (HOOK) Board of Directors have after the changes?
When do the Board changes at HOOKIPA Pharma (HOOK) take effect?
